Seeking to boost shareholder returns, Novartis readies new $11B buyback round

Just as Swiss drug giant Novartis works to wrap up one massive share buyback program, the company has decided to roll out another.

Novartis is preparing to kick off a share buyback round aimed at repurchasing up to 10 billion Swiss francs ($11 billion) worth of company shares in the next three years.